Strong Revenue and EBITDA Growth
Q2 2025 revenue increased by $50.8 million or 30.1% to $219.5 million, and adjusted EBITDA increased by $3.2 million or 24.5% over the prior year quarter.
Home Health and Hospice Segment Performance
Segment revenue was $166 million, a 32.5% increase, and adjusted EBITDA was $25.5 million, a 29.9% increase. Hospice revenue was $73.8 million, a 24.3% increase, and admits increased by 14.7%.
Senior Living Segment Improvement
Revenue improved to $53.5 million, a 23.1% increase, with adjusted EBITDA improving by 25.7% over the prior year.
Acquisitions and Expansion
Announced purchase of divested assets from Amedisys and UnitedHealth Group, expanding presence in the Southeast U.S. and increasing capacity for future growth.
Raised Annual Guidance
Full-year revenue guidance increased to $852.8 million to $887.6 million, with adjusted EPS expected between $1.09 and $1.15, a 19.1% increase over 2024.